1. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes

2. Overview

3. Case 1: Antiplatelet Strategy for High-Risk PCI of STEMI

4. P2Y12 Inhibitor Pretreatment Concerns

5. Pros and Cons of Upstream vs Downstream Use of P2Y12 Receptor Inhibitors

6. Novel Oral P2Y12 Effects in Patients With STEMI

7. Is Drug "Crushing" a Viable Pretreatment Strategy?

8. Other Pretreatment Strategies

9. Case 2: Antiplatelet Strategies for STEMI and Cardiogenic Shock

10. IV Antiplatelet Agents: Cangrelor vs GPIs

11. Expert Consensus Recommendations on Switching

12. Cangrelor Platelet Reactivity by Day

13. STEMI Without CS: Crushed Oral vs IV P2Y12 Inhibitors

14. Propensity-Matched Analysis Comparing Cangrelor Alone vs Clopidogrel Plus GPIs in the CHAMPION Trials

15. CHAMPION: Pooled Acquired Thrombocytopenia (TCP) 48-Hour Ischemic Outcomes, Stratified By Acquired TCP

16. Strategies for Patients With NSTEMI and UA

17. Strategies for Complex PCI

18. Cangrelor to Thienopyridine Transition

19. Cangrelor to Ticagrelor Transition

20. Team-Based Strategies

21. Abbreviations

22. Abbreviations (cont)